|Over a week ago|
MorphoSys downgraded to Neutral from Buy at Citi » 04:4009/2709/27/21
Citi analyst Vineet…
Citi analyst Vineet Agrawal downgraded MorphoSys to Neutral from Buy with a EUR 52 price target. The stock is down 56% year-to-date on the "lackluster" Monjuvi launch but there is few near-term catalysts to change investor sentiment, Agrawal tells investors in a research note.
|Over a month ago|
MorphoSys participates in a conference call with JPMorgan » 10:0209/2309/23/21
European Pharma &…
European Pharma & Biotech Analyst holds a conference call with CEO Kress on September 23 at 11 am hosted by JPMorgan.
MorphoSys reinstated with a Neutral at Goldman Sachs » 04:4509/1309/13/21
Goldman Sachs analyst…
Goldman Sachs analyst Graig Suvannavejh reinstated coverage of MorphoSys with a Neutral rating and $12 price target following the closing of the acquisition of Constellation Pharma. The deal adds meaningful operating expenditures, which pushes out the company's first-year profitability, Suvannavejh tells investors in a research note. The analyst awaits an inflection in sales of Monjuvi, and with meaningful late-stage clinical data read outs not expected until 2024-2025, he sees MorphoSys as a "show me" story.
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays » 13:5209/0209/02/21
Barclays analyst Emmanuel…
Barclays analyst Emmanuel Papadakis lowered the firm's price target on MorphoSys to EUR 47 from EUR 90 and keeps an Equal Weight rating on the shares.
Fly Intel: After-Hours Movers » 18:2708/2608/26/21
BILL, GPS, LTRX, WDAY, MOR, OLLI, DOMO, PTON, VMW, MRVL, DELL, HPQ
Check out this evening's…
MorphoSys spikes 6% after EC grants conditional MA for Minjuvi combo treatment » 17:2508/2608/26/21
Shares of MorphoSys (MOR)…
Shares of MorphoSys (MOR) are up approximately 6% or 87c per share to $15.00 per share in after hours trading after Incyte (INCY) and MorphoSy announced that the European Commission or EC, has granted conditional marketing authorization for Minjuvi or tafasitamab, in combination with lenalidomide for certain DLBCL treatment.
MorphoSys, Incyte get EC conditional MA for Minjuvi-lenalidomide combo for DLBCL » 16:1508/2608/26/21
MorphoSys (MOR) and…
MorphoSys (MOR) and Incyte (INCY) announced that the European Commission has granted conditional marketing authorization for Minjuvi, tafasitamab, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant . The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2021 recommending the conditional marketing authorization of Minjuvi. "People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis. However, with the EC's approval of Minjuvi, eligible patients now have a new and much needed treatment option," said Herve Hoppenot, Chief Executive Officer, Incyte. "We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment." "The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, "said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. "DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse after initial therapy." The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant . The results showed best objective response rate of 56.8%, primary endpoint, including a complete response rate of 39.5% and a partial response rate of 17.3%, as assessed by an independent review committee. The median duration of response was 43.9 months after a minimum follow up of 35 months, secondary endpoint. Tafasitamab together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for tafasitamab include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.
MorphoSys downgraded to Hold from Buy at Deutsche Bank » 04:5108/0608/06/21
Deutsche Bank analyst…
Deutsche Bank analyst Rajan Sharma downgraded MorphoSys to Hold from Buy with a price target of EUR 46, down from EUR 116. The Q2 results brought a "clear negative signal" from management on short to medium-term Monjuvi expectations, Sharma tells investors in a research note. The guidance cut, balance sheet liability reduction attributable to Monjuvi profits and subsequent call commentary suggest that the drivers of Monjuvi's disappointing launch go beyond the challenges posed by the pandemic and "call into question the company's commercialization strategy," says the analyst. As such, Sharma sees a lack of catalysts for MorphoSys shares.
MorphoSys downgraded to Hold from Buy at Deutsche Bank » 15:2908/0508/05/21
Deutsche Bank analyst…
Deutsche Bank analyst Rajan Sharma downgraded MorphoSys to Hold from Buy.
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley » 14:1208/0408/04/21
Morgan Stanley analyst…
Morgan Stanley analyst James Quigley lowered the firm's price target on MorphoSys to EUR 75 from EUR 86 and keeps an Overweight rating on the shares.